{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:40:46Z","timestamp":1791330046888,"version":"4.3.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The design of clinical trials in rare diseases is often complicated by a lack of real-world translational knowledge. Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by skeletal malformations and progressive heterotopic ossification (HO). Palovarotene is a selective retinoic acid receptor gamma agonist. Here, we describe the methodology of three studies in the palovarotene clinical development program in FOP and discuss insights that could inform future research, including endpoint suitability and the impact of trial design.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PVO-1A-001 (NCT02322255) was a prospective, protocol-specified, longitudinal FOP natural history study (NHS). PVO-1A-201 (NCT02190747) was a randomized, double-blind, placebo-controlled phase II trial; PVO-1A-202 (NCT02279095) was its open-label extension. Trial designs, including treatment regimens and imaging assessments, were refined between PVO-1A-201 and PVO-\u200d1A-202, and within PVO-1A-202, based on emerging data as the studies progressed. Palovarotene doses were administered using a flare-up treatment regimen (higher dose for 2\/4 weeks, followed by lower dose for 4\/\u22658 weeks; from flare-up onset), with or without accompanying chronic (daily) treatment. Flare-up and disease progression outcomes were assessed, including incidence and volume of new HO during flare-ups and\/or annually, as well as other clinical, patient-reported, and exploratory outcomes. Safety was monitored throughout all studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 114 and 58 individuals with FOP were enrolled in the NHS and phase II trials, respectively. Results of the NHS and PVO-1A-201 were published in 2022; complete results of PVO-1A-202 will be publicly available in due course. Together the studies yielded important information on endpoint suitability, including that low-dose whole-body computed tomography was the optimum imaging modality for assessing HO progression annually and that long study durations are needed to detect substantial changes in functional and patient-reported outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A flexible clinical development program is necessary for underexplored rare diseases to overcome the many challenges faced. Here, the NHS provided a longitudinal evaluation of FOP progression and interventional trials were based on emerging data. The studies described informed the design and endpoints implemented in the phase\u00a0III MOVE trial (NCT03312634) and provide a foundation for future clinical trial development.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT02322255 (registered 23\/12\/2014); NCT02190747 (registered 15\/07\/2014); NCT02279095 (registered 30\/10\/2014).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12874-023-02080-7","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T09:01:47Z","timestamp":1699866107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva"],"prefix":"10.1186","volume":"23","author":[{"given":"Robert J.","family":"Pignolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al Mukaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Baujat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"De Cunto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim-Hanh","family":"Le Quan Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna R.","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Strahs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"issue":"1","key":"2080_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13023-019-1002-z","volume":"14","author":"CMW van der Gaasterland","year":"2019","unstructured":"van der Gaasterland CMW, du Prie-Olthof MJ, Donk M, Kaatee MM, Kaczmarek R, et al. The patient\u2019s view on rare Disease trial design - a qualitative study. Orphanet J Rare Dis. 2019;14(1):31.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2080_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13023-018-0931-2","volume":"13","author":"S Day","year":"2018","unstructured":"Day S, Jonker AH, Lau LPL, Hilgers R-D, Irony I, Larsson K, et al. Recommendations for the design of small population clinical trials. Orphanet J Rare Dis. 2018;13(1):195.","journal-title":"Orphanet J Rare Dis"},{"key":"2080_CR3","unstructured":"OMIM.org. OMIM #135100. https:\/\/www.omim.org\/entry\/135100. Accessed October 2021."},{"issue":"1","key":"2080_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13023-017-0674-5","volume":"12","author":"G Baujat","year":"2017","unstructured":"Baujat G, Choquet R, Bouee S, Jeanbat V, Courouve L, Ruel A, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12(1):123.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2080_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1136\/jmg.19.1.35","volume":"19","author":"JM Connor","year":"1982","unstructured":"Connor JM, Evans DA. Genetic aspects of fibrodysplasia ossificans progressiva. J Med Genet. 1982;19(1):35\u20139.","journal-title":"J Med Genet"},{"issue":"2","key":"2080_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.29245\/2572-9411\/2020\/2.1196","volume":"5","author":"M Liljesthr\u00f6m","year":"2020","unstructured":"Liljesthr\u00f6m M, Pignolo RJ, Kaplan FS. Epidemiology of the global fibrodysplasia ossificans progressiva (FOP) community. J Rare Dis Res Treat. 2020;5(2):31\u20136.","journal-title":"J Rare Dis Res Treat"},{"issue":"1","key":"2080_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-021-01983-2","volume":"16","author":"RJ Pignolo","year":"2021","unstructured":"Pignolo RJ, Hsiao EC, Baujat G, Lapidus D, Sherman A, Kaplan FS. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet J Rare Dis. 2021;16(1):350.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2080_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","volume":"31","author":"RJ Pignolo","year":"2016","unstructured":"Pignolo RJ, Bedford-Gay C, Liljesthrom M, Durbin-Johnson BP, Shore EM, Rocke DM, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31(3):650\u20136.","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"2080_CR9","first-page":"437","volume":"10","author":"RJ Pignolo","year":"2013","unstructured":"Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013;10(Suppl 2):437\u201348.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"3","key":"2080_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2106\/JBJS.I.00705","volume":"92","author":"FS Kaplan","year":"2010","unstructured":"Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92(3):686\u201391.","journal-title":"J Bone Joint Surg Am"},{"key":"2080_CR11","first-page":"1","volume":"2","author":"FS Kaplan","year":"2021","unstructured":"Kaplan FS, Al Mukaddam M, Baujat G, Brown M, Cali A, Cho TJ, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Int Clin Council FOP. 2021;2:1\u2013128.","journal-title":"Proc Int Clin Council FOP"},{"issue":"5","key":"2080_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J, Choi IH, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525\u20137.","journal-title":"Nat Genet"},{"issue":"5\u20136","key":"2080_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cytogfr.2009.10.006","volume":"20","author":"FS Kaplan","year":"2009","unstructured":"Kaplan FS, Pignolo RJ, Shore EM. The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine Growth Factor Rev. 2009;20(5\u20136):399\u2013407.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"2080_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2013.09.002","volume":"57","author":"W Zhang","year":"2013","unstructured":"Zhang W, Zhang K, Song L, Pang J, Ma H, Shore EM, et al. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013;57(2):386\u201391.","journal-title":"Bone"},{"issue":"11","key":"2080_CR15","first-page":"3462","volume":"119","author":"Q Shen","year":"2009","unstructured":"Shen Q, Little SC, Xu M, Haupt J, Ast C, Katagiri T, et al. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Investig. 2009;119(11):3462\u201372.","journal-title":"J Clin Investig"},{"issue":"303","key":"2080_CR16","doi-asserted-by":"publisher","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","volume":"7","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell SJ, Idone V, Wolken DM, Huang L, Kim HJ, Wang L, et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015;7(303):303ra137.","journal-title":"Sci Transl Med"},{"issue":"9","key":"2080_CR17","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jbmr.2820","volume":"31","author":"SA Chakkalakal","year":"2016","unstructured":"Chakkalakal SA, Uchibe K, Convente MR, Zhang D, Economides AN, Kaplan FS, et al. Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) fibrodysplasia ossificans progressiva (FOP) mutation. J Bone Miner Res. 2016;31(9):1666\u201375.","journal-title":"J Bone Miner Res"},{"key":"2080_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1749-6632.2011.06195.x","volume":"1237","author":"FS Kaplan","year":"2011","unstructured":"Kaplan FS, Lounev VY, Wang H, Pignolo RJ, Shore EM. Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis. Ann N Y Acad Sci. 2011;1237:5\u201310.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"2080_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nm.2334","volume":"17","author":"K Shimono","year":"2011","unstructured":"Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med. 2011;17(4):454\u201360.","journal-title":"Nat Med"},{"key":"2080_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bone.2017.09.016","volume":"109","author":"CM Lindborg","year":"2018","unstructured":"Lindborg CM, Brennan TA, Wang H, Kaplan FS, Pignolo RJ. Cartilage-derived retinoic acid-sensitive protein (CD-RAP): a stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP). Bone. 2018;109:153\u20137.","journal-title":"Bone"},{"key":"2080_CR21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/DDDT.S289772","volume":"15","author":"A Burton","year":"2021","unstructured":"Burton A, Casta\u00f1o A, Bruno M, Riley S, Schumacher J, Sultan MB, et al. Drug discovery and development in rare Diseases: taking a closer look at the tafamidis story. Drug Des Devel Ther. 2021;15:1225\u201343.","journal-title":"Drug Des Devel Ther"},{"key":"2080_CR22","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.2147\/DDDT.S139601","volume":"11","author":"DAH Whiteman","year":"2017","unstructured":"Whiteman DAH, Kimura A. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future. Drug Des Devel Ther. 2017;11:2467\u201380.","journal-title":"Drug Des Devel Ther"},{"key":"2080_CR23","unstructured":"ClinicalTrials.gov. Identifier: NCT02322255. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02322255. Accessed October 2021."},{"issue":"12","key":"2080_CR24","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.gim.2022.08.013","volume":"24","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, Baujat G, Brown MA, De Cunto C, Hsiao EC, Keen R, et al. The natural history of fibrodysplasia ossificans progressiva: a prospective, global 36-month study. Genet Med. 2022;24(12):2422\u201333.","journal-title":"Genet Med"},{"key":"2080_CR25","unstructured":"ClinicalTrials.gov. Identifier: NCT02190747. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02190747. Accessed October 2021."},{"issue":"10","key":"2080_CR26","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/jbmr.4655","volume":"37","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, Baujat G, Hsiao EC, Keen R, Wilson A, Packman J, et al. Palovarotene for fibrodysplasia ossificans progressiva (FOP): results of a randomized, placebo-controlled, double-blind phase 2 trial. J Bone Miner Res. 2022;37(10):1891\u2013902.","journal-title":"J Bone Miner Res"},{"key":"2080_CR27","unstructured":"ClinicalTrials.gov. Identifier: NCT02279095. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02279095. Accessed October 2021."},{"key":"2080_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bone.2017.04.015","volume":"101","author":"FS Kaplan","year":"2017","unstructured":"Kaplan FS, Al Mukaddam M, Pignolo RJ. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone. 2017;101:123\u20138.","journal-title":"Bone"},{"issue":"3","key":"2080_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.acra.2016.10.010","volume":"24","author":"CS Rajapakse","year":"2017","unstructured":"Rajapakse CS, Lindborg C, Wang H, Newman BT, Kobe EA, Chang G, et al. Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia ossificans Progressiva. Acad Radiol. 2017;24(3):321\u20137.","journal-title":"Acad Radiol"},{"key":"2080_CR30","unstructured":"ClinicalTrials.gov. Identifier: NCT02979769. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02979769. Accessed March 2022."},{"issue":"6","key":"2080_CR31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00223-021-00877-6","volume":"109","author":"SE Warner","year":"2021","unstructured":"Warner SE, Kaplan FS, Pignolo RJ, Smith SE, Hsiao EC, De Cunto C, et al. Whole-body computed tomography versus dual energy X\u2013ray absorptiometry for assessing heterotopic ossification in fibrodysplasia ossificans progressiva. Calcif Tissue Int. 2021;109(6):615\u201325.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2080_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13023-019-1068-7","volume":"14","author":"RJ Pignolo","year":"2019","unstructured":"Pignolo RJ, Baujat G, Brown MA, De Cunto C, Di Rocco M, Hsiao EC, et al. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019;14(1):98.","journal-title":"Orphanet J Rare Dis"},{"key":"2080_CR33","doi-asserted-by":"publisher","first-page":"116642","DOI":"10.1016\/j.bone.2022.116642","volume":"168","author":"RJ Pignolo","year":"2023","unstructured":"Pignolo RJ, Kimel M, Whalen J, Kawata AK, Artyomenko A, Kaplan FS. The Fibrodysplasia ossificans Progressiva physical function questionnaire (FOP-PFQ): a patient-reported, disease-specific measure. Bone. 2023;168:116642.","journal-title":"Bone"},{"issue":"7","key":"2080_CR34","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","volume":"18","author":"RD Hays","year":"2009","unstructured":"Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18(7):873\u201380.","journal-title":"Qual Life Res"},{"issue":"4","key":"2080_CR35","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s11136-013-0581-8","volume":"23","author":"CB Forrest","year":"2014","unstructured":"Forrest CB, Bevans KB, Pratiwadi R, Moon J, Teneralli RE, Minton JM, et al. Development of the PROMIS\u00ae pediatric global health (PGH-7) measure. Qual Life Res. 2014;23(4):1221\u201331.","journal-title":"Qual Life Res"},{"issue":"12","key":"2080_CR36","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266\u201377.","journal-title":"Am J Psychiatry"},{"key":"2080_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bone.2016.02.008","volume":"90","author":"S Sinha","year":"2016","unstructured":"Sinha S, Uchibe K, Usami Y, Pacifici M, Iwamoto M. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent. Bone. 2016;90:59\u201368.","journal-title":"Bone"},{"issue":"2","key":"2080_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1183\/09031936.00161911","volume":"40","author":"J Stolk","year":"2012","unstructured":"Stolk J, Stockley RA, Stoel BC, Cooper BG, Piitulainen E, Seersholm N, et al. Randomised controlled trial for Emphysema with a selective agonist of the \u03b3-type retinoic acid receptor. Eur Respir J. 2012;40(2):306\u201312.","journal-title":"Eur Respir J"},{"issue":"11","key":"2080_CR39","first-page":"1243","volume":"10","author":"M Hind","year":"2009","unstructured":"Hind M, Stinchcombe S. Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of Emphysema. Curr Opin Investig Drugs. 2009;10(11):1243\u201350.","journal-title":"Curr Opin Investig Drugs"},{"key":"2080_CR40","unstructured":"ClinicalTrials.gov. Identifier: NCT03312634. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03312634. Accessed October 2021."},{"issue":"3","key":"2080_CR41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jbmr.4762","volume":"38","author":"RJ Pignolo","year":"2023","unstructured":"Pignolo RJ, Hsiao EC, Al Mukaddam M, Baujat G, Berglund SK, Brown MA, et al. Reduction of new heterotopic ossification (HO) in the open-label, phase 3 MOVE trial of palovarotene for fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res. 2023;38(3):381\u201394.","journal-title":"J Bone Miner Res"},{"key":"2080_CR42","unstructured":"ClinicalTrials.gov. Identifier: NCT0318866. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03188666. Accessed October 2021."},{"key":"2080_CR43","unstructured":"ClinicalTrials.gov. Identifier: NCT05039515. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05039515. Accessed October 2021."},{"key":"2080_CR44","unstructured":"ClinicalTrials.gov. Identifier: NCT04307953. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04307953. Accessed October 2021."},{"key":"2080_CR45","unstructured":"UMIN-CTR. UMIN000028429. https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr_view.cgi?recptno=R000032495. Accessed October 2021."},{"key":"2080_CR46","unstructured":"ClinicalTrials.gov. Identifier: NCT05090891. https:\/\/clinicaltrials.gov\/study\/NCT05090891. Accessed July 2023."},{"issue":"6","key":"2080_CR47","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/bcp.13777","volume":"85","author":"EC Hsiao","year":"2019","unstructured":"Hsiao EC, Di Rocco M, Cali A, Zasloff M, Al Mukaddam M, Pignolo RJ, et al. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol. 2019;85(6):1199\u2013207.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-023-02080-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-023-02080-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-023-02080-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T09:02:36Z","timestamp":1699866156000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-023-02080-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2080"],"URL":"https:\/\/doi.org\/10.1186\/s12874-023-02080-7","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"22 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies described here were conducted in accordance with the principles that have their origin in the Declaration of Helsinki, inclusive of any subsequent amendment(s), and that are consistent with the International Council for Harmonization (ICH) Good Clinical Practice (GCP), European Union Directive 2001\/20\/EC, United States Food and Drug Administration (FDA) Code of Federal Regulations, and other applicable local regulatory requirement(s), whichever affords greater patient protection. The original protocol, all protocol amendments, and informed consent\/assent forms and updates were reviewed and approved by the corresponding Institutional Review Board (IRB) or Independent Ethics Committee (IEC) at each site in accordance with local regulatory requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The IRBs\/IECs that reviewed and approved the study documents for PVO-1A-001 were: University of Pennsylvania Office of Regulatory Affairs, US; Human Research Protection Program Institutional Review Board, University of California San Francisco, US; Comit\u00e9 de Protection des Personnes \u00cele de France II, H\u00f4pital Necker Enfants Malades, France; Comitato Etico Regionale, IRCCS AOU San Martino IST, Italy; Comite de Etica de Protocolos de Investigacion, Hospital Italiano de Buenos Aires, Argentina; London \u2013 Stanmore Research Ethics Committee, Health Research Authority, UK; and Metro South Human Research Ethics Committee, Australia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The IRBs\/IECs that reviewed and approved the trial documents for PVO-1A-201 were: Ethics Committee \u00cele de France VIII, France; Human Research Protection Program Committee on Human Research, University of California, San Francisco, US; Institutional Review Board, University of Pennsylvania, US; and NRES Committee South East Coast \u2013 Brighton & Sussex, UK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The IRBs\/IECs that reviewed and approved the study documents for PVO-1A-202 were: University of Pennsylvania Institutional Review Board, US; University of California San Francisco Human Research Protection Program Institutional Review Board, US; Mayo Clinic Institutional Review Boards, US; Comit\u00e9 de Protection des Personnes \u00cele de France VIII, H\u00f4pital Ambroise Par\u00e9, France; NHS Health Research Authority London \u2013 Brighton & Sussex Research Ethics Committee, UK; Comit\u00e9 de \u00c9tica de Protocolos de Investigacion, Argentina; and Metro South Human Research Ethics Committee, Australia.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Prior to participation in the studies, the Investigator and\/or delegate fully explained to the patients and\/or parents all aspects of the study that were relevant to the decision to participate. Informed consent was sent to the patients and\/or parents for reading and reflection, and was documented by means of a written, signed, and dated consent form, prior to study initiation.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"These studies were sponsored by Ipsen. Ipsen contributed to the design of the studies, the collection, analysis, and interpretation of data, and the writing of the manuscript. All costs associated with development of this manuscript were funded by Ipsen. In April 2019, Ipsen acquired Clementia Pharmaceuticals.<b>RJP<\/b>: Research investigator: Clementia\/Ipsen, Regeneron; Advisory board: President of the International Clinical Council on FOP; <b>MAM<\/b>: Research support: Clementia\/Ipsen, Regeneron; Non-paid consultant: Biocryst, Blueprint Medicines, Daiichi Sankyo, Incyte, Keros; Advisory board (all voluntary): IFOPA Registry Medical Advisory Board, Incyte, International Clinical Council on FOP; Non-restricted educational fund from Excel and Catalyst sponsored by Ipsen; <b>GB<\/b>: Advisory board: Clementia\/Ipsen, FOP European Consortium, International Clinical Council on FOP; Speaker: Clementia\/Ipsen; <b>MAB<\/b>: Advisory board: Abbvie, Janssen, Pfizer, UCB Pharma, Novartis, Xinthera; Grant support: Abbvie; Research investigator: Abbvie, Clementia\/Ipsen, Janssen, Novartis, Pathios, Regeneron; Data Monitoring Safety Committee: Incyte, Ipsen, Regeneron; Speaker: Abbvie, Janssen, Novartis, Pfizer, Regeneron, UCB Pharma; <b>CDC<\/b>: Research investigator: Clementia\/Ipsen; Speaker: Novartis; <b>ECH<\/b>: Advisory board (all voluntary): Fibrous Dysplasia Foundation, IFOPA Registry medical advisory board, International Clinical Council on FOP; Clinical research support: Clementia\/Ipsen, Neurocrine Biosciences Inc., Regeneron; Research investigator: Clementia\/Ipsen; <b>RK<\/b>: Research investigator: Ipsen\/Clementia, Kyowa Kirin, Regeneron; Advisory board: IFOPA FOP Registry Medical Advisory Board, International Clinical Council on FOP; <b>K\u2011HLQS<\/b>: Coordinator of Ipsen FOP-program and MO-trial; <b>DRG<\/b>: Chief Medical Officer of Clementia and a shareholder at the time these data were obtained; <b>RM<\/b>: Employee of Ipsen; <b>ARS<\/b>: Employee of Ipsen; <b>FSK<\/b>: Research investigator: Clementia\/Ipsen, Regeneron; Advisory Board: IFOPA Medical Advisory Board; Founder and Immediate Past-President of the International Clinical Council on FOP; Chair of the Publications Committee of the International Clinical Council. In April 2019, Ipsen acquired Clementia Pharmaceuticals.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"269"}}